Implantation of first patient in Germany
Pixium Vision announces the successful first implantation of a patient in Germany in the PRIMAvera pivotal trial.
- Successful first implantation of a patient in the PRIMAvera study in Germany
- PRIMAvera clinical sites opening in five locations in Germany
- Additional clinical sites to open in additional European countries
This follows approval of the PRIMAvera study by Germany’s Federal Institute for Drugs and Medical Devices, which aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. PRIMAvera clinical sites have now opened in Bonn, Sulzbach, Hamburg, Munich and Ludwigshafen with one more in Tuebingen to follow. The PRIMAvera study was initiated in Q4 2020 and the first patient was implanted in March 2021.
Pixium Vision supports La Marche Nationale pour la Vue 2021
Pixium Vision supports LA MARCHE NATIONALE POUR LA VUE which will start in Paris on Saturday, October 9th.
Departure from Place Stalingrad at 2 pm (metro Stalingrad)
Arrival at Place de la Porte de Bagnolet (metro Porte de Bagnolet) around 4:30 pm
A dream walk of about 7 km to support research:
• A bit of canal Saint Martin,
• The Saint-Louis Hospital,
• Belleville Park (it goes up a bit),
• Flirt with Père Lachaise,
• Saint-Germain de Charonne church,
• Porte de Bagnolet
Sign up and come!!!
Pixium Vision expands collaboration with Stanford University on next generation Prima System implants
Pixium Vision announces today expansion of collaboration with the academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD).
- New implants to leverage existing PRIMA design and significantly improve implant resolution
- Collaboration expands existing agreement between Pixium Vision and Stanford University
Executive interview with Pooya Hemani, Healthcare analyst Edison
In this interview, chief executive officer Lloyd Diamond and chief financial officer Offer Nonhoff discuss how PRIMA differentiates itself from earlier-generation retinal implants, and provide details on the ongoing PRIMAvera study as well as the planned commercial strategy for the US and key European markets.
They also review the company’s financial position and objectives, and comment on longer-term development opportunities. Finally, the company’s executives highlight some of the key catalysts and milestones expected over the next year.